Latest Breaking News On - Integrative sciences at celgene - Page 1 : comparemela.com

ARTBIO Announces Appointment of Nick Pullen, Ph D , as Chief Scientific Officer

Management expansion strengthens capabilities in developing new class of alpha radioligand therapies

United kingdomCity ofNick pullenEmanuele ostuniIntegrative sciences at celgeneUniversity of osloPrnewswire artbio incFriedrich miescher institute in baselUniversity of southamptonHead of research at jnana therapeuticsChief scientificChief executive officerSenior vice presidentVice presidentIntegrative sciencesFriedrich miescher institute

ARTBIO Announces Appointment of Nick Pullen, Ph D , as Chief Scientific Officer

/PRNewswire/ ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today.

United kingdomCity ofNick pullenEmanuele ostuniUniversity of southamptonHead of research at jnana therapeuticsIntegrative sciences at celgeneUniversity of osloPrnewswire artbio incFriedrich miescher institute in baselChief scientificChief executive officerSenior vice presidentVice presidentIntegrative sciencesFriedrich miescher institute

ARTBIO Announces Appointment of Nick Pullen, Ph D , as Chief Scientific Officer

ARTBIO Announces Appointment of Nick Pullen, Ph D , as Chief Scientific Officer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofNick pullenEmanuele ostuniIntegrative sciences at celgeneHead of research at jnana therapeuticsPrnewswire artbio incUniversity of southamptonFriedrich miescher institute in baselUniversity of osloChief scientificChief executive officerSenior vice presidentVice presidentIntegrative sciencesFriedrich miescher institute

ARTBIO Announces Appointment of Nick Pullen, Ph D , as Chief Scientific Officer

Management expansion strengthens capabilities in developing new class of alpha radioligand therapies CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ ARTBIO, Inc.

City ofUnited kingdomNick pullenEmanuele ostuniIntegrative sciences at celgeneHead of research at jnana therapeuticsPrnewswire artbio incUniversity of osloFriedrich miescher institute in baselUniversity of southamptonChief scientificChief executive officerSenior vice presidentVice presidentIntegrative sciencesFriedrich miescher institute

ARTBIO Announces Appointment of Nick Pullen, Ph D , as Chief Scientific Officer

/PRNewswire/ ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today.

United kingdomCity ofEmanuele ostuniNick pullenUniversity of osloIntegrative sciences at celgeneUniversity of southamptonHead of research at jnana therapeuticsPrnewswire artbio incFriedrich miescher institute in baselChief scientificChief executive officerSenior vice presidentVice presidentIntegrative sciencesFriedrich miescher institute